Effectiveness and safety of topical levodopa in a chick model of myopia

Kate Thomson, Cindy Karouta, Ian Morgan, Tamsin Kelly, Regan Ashby

Research output: Contribution to journalArticle

Abstract

Animal models have demonstrated a link between dysregulation of the retinal dopamine system and the excessive ocular growth associated with the development of myopia. Here we show that intravitreal or topical application of levodopa, which is widely used in the treatment of neurological disorders involving dysregulation of the dopaminergic system, inhibits the development of experimental myopia in chickens. Levodopa slows ocular growth in a dose dependent manner in chicks with a similar potency to atropine, a common inhibitor of ocular growth in humans. Topical levodopa remains effective over chronic treatment periods, with its effectiveness enhanced by coadministration with carbidopa to prevent its premature metabolism. No changes in normal ocular development (biometry and refraction), retinal health (histology), or intraocular pressure were observed in response to chronic treatment (4 weeks). With a focus on possible clinical use in humans, translation of these avian safety findings to a mammalian model (mouse) illustrate that chronic levodopa treatment (9 months) does not induce any observable changes in visual function (electroretinogram recordings), ocular development, and retinal health, suggesting that levodopa may have potential as a therapeutic intervention for human myopia.

Original languageEnglish
Article number18345
Pages (from-to)1-17
Number of pages17
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 4 Dec 2019

Fingerprint

Myopia
Levodopa
Safety
Carbidopa
Biometry
Therapeutics
Growth Inhibitors
Health
Growth
Nervous System Diseases
Intraocular Pressure
Atropine
Chickens
Dopamine
Histology
Animal Models

Cite this

Thomson, Kate ; Karouta, Cindy ; Morgan, Ian ; Kelly, Tamsin ; Ashby, Regan. / Effectiveness and safety of topical levodopa in a chick model of myopia. In: Scientific Reports. 2019 ; Vol. 9, No. 1. pp. 1-17.
@article{f1e9b0c443684acd80193482d537f460,
title = "Effectiveness and safety of topical levodopa in a chick model of myopia",
abstract = "Animal models have demonstrated a link between dysregulation of the retinal dopamine system and the excessive ocular growth associated with the development of myopia. Here we show that intravitreal or topical application of levodopa, which is widely used in the treatment of neurological disorders involving dysregulation of the dopaminergic system, inhibits the development of experimental myopia in chickens. Levodopa slows ocular growth in a dose dependent manner in chicks with a similar potency to atropine, a common inhibitor of ocular growth in humans. Topical levodopa remains effective over chronic treatment periods, with its effectiveness enhanced by coadministration with carbidopa to prevent its premature metabolism. No changes in normal ocular development (biometry and refraction), retinal health (histology), or intraocular pressure were observed in response to chronic treatment (4 weeks). With a focus on possible clinical use in humans, translation of these avian safety findings to a mammalian model (mouse) illustrate that chronic levodopa treatment (9 months) does not induce any observable changes in visual function (electroretinogram recordings), ocular development, and retinal health, suggesting that levodopa may have potential as a therapeutic intervention for human myopia.",
keywords = "Myopia, Dopamine, Levodopa, pharmacotherapy, Vision Disorders/diagnosis",
author = "Kate Thomson and Cindy Karouta and Ian Morgan and Tamsin Kelly and Regan Ashby",
year = "2019",
month = "12",
day = "4",
doi = "10.1038/s41598-019-54789-5",
language = "English",
volume = "9",
pages = "1--17",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Effectiveness and safety of topical levodopa in a chick model of myopia. / Thomson, Kate; Karouta, Cindy; Morgan, Ian; Kelly, Tamsin; Ashby, Regan.

In: Scientific Reports, Vol. 9, No. 1, 18345, 04.12.2019, p. 1-17.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effectiveness and safety of topical levodopa in a chick model of myopia

AU - Thomson, Kate

AU - Karouta, Cindy

AU - Morgan, Ian

AU - Kelly, Tamsin

AU - Ashby, Regan

PY - 2019/12/4

Y1 - 2019/12/4

N2 - Animal models have demonstrated a link between dysregulation of the retinal dopamine system and the excessive ocular growth associated with the development of myopia. Here we show that intravitreal or topical application of levodopa, which is widely used in the treatment of neurological disorders involving dysregulation of the dopaminergic system, inhibits the development of experimental myopia in chickens. Levodopa slows ocular growth in a dose dependent manner in chicks with a similar potency to atropine, a common inhibitor of ocular growth in humans. Topical levodopa remains effective over chronic treatment periods, with its effectiveness enhanced by coadministration with carbidopa to prevent its premature metabolism. No changes in normal ocular development (biometry and refraction), retinal health (histology), or intraocular pressure were observed in response to chronic treatment (4 weeks). With a focus on possible clinical use in humans, translation of these avian safety findings to a mammalian model (mouse) illustrate that chronic levodopa treatment (9 months) does not induce any observable changes in visual function (electroretinogram recordings), ocular development, and retinal health, suggesting that levodopa may have potential as a therapeutic intervention for human myopia.

AB - Animal models have demonstrated a link between dysregulation of the retinal dopamine system and the excessive ocular growth associated with the development of myopia. Here we show that intravitreal or topical application of levodopa, which is widely used in the treatment of neurological disorders involving dysregulation of the dopaminergic system, inhibits the development of experimental myopia in chickens. Levodopa slows ocular growth in a dose dependent manner in chicks with a similar potency to atropine, a common inhibitor of ocular growth in humans. Topical levodopa remains effective over chronic treatment periods, with its effectiveness enhanced by coadministration with carbidopa to prevent its premature metabolism. No changes in normal ocular development (biometry and refraction), retinal health (histology), or intraocular pressure were observed in response to chronic treatment (4 weeks). With a focus on possible clinical use in humans, translation of these avian safety findings to a mammalian model (mouse) illustrate that chronic levodopa treatment (9 months) does not induce any observable changes in visual function (electroretinogram recordings), ocular development, and retinal health, suggesting that levodopa may have potential as a therapeutic intervention for human myopia.

KW - Myopia

KW - Dopamine

KW - Levodopa

KW - pharmacotherapy

KW - Vision Disorders/diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85076109559&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-54789-5

DO - 10.1038/s41598-019-54789-5

M3 - Article

VL - 9

SP - 1

EP - 17

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 18345

ER -